Needa Brown
Sponsor: DOD/USAMRAA
Combination Intraperitoneal Local Delivery of PARPi Implants and Anti-PDL1 |
| Aggressive metastatic ovarian cancer patients have limited therapy options and clinical trials to evaluate promising alternative combinations have been limited due to the high toxicity. Here we propose a bio/nanoformulation approach to delivery PARPi directly into the peritoneal cavity for sustained release and limited toxicity in combination with innate and adaptive immune modulating nanoparticles of ADU-S100 and anti-PDL1. |